LYMPHIR (denileukin diftitox-cxdl)

About Citius Oncology, Inc.

Citius Oncology is a NASDAQ-listed biopharmaceutical company (CTOR) focused on advancing LYMPHIR, an IL-2 receptor-directed diphtheria toxin fusion protein for T-cell lymphomas. Following FDA approval in 2024, the company is preparing for U.S. commercial launch in partnership with Dr. Reddy’s Laboratories, targeting a $400+ million market. With a well-characterized mechanism and a streamlined regulatory pathway, Citius Oncology aims to expand into peripheral T-cell lymphoma and build a broader hematology oncology franchise.

About Citius Oncology, Inc.

Citius Oncology is a NASDAQ-listed biopharmaceutical company (CTOR) focused on advancing LYMPHIR, an IL-2 receptor-directed diphtheria toxin fusion protein for T-cell lymphomas. Following FDA approval in 2024, the company is preparing for U.S. commercial launch in partnership with Dr. Reddy’s Laboratories, targeting a $400+ million market. With a well-characterized mechanism and a streamlined regulatory pathway, Citius Oncology aims to expand into peripheral T-cell lymphoma and build a broader hematology oncology franchise.

About Citius Oncology

Citius Oncology is a biopharmaceutical company with a mission to develop and commercialize targeted oncology therapies by focusing on programs with potentially reduced development and clinical risks. Its defining achievement is the FDA approval of LYMPHIR™ (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma (CTCL) in August 2024, transitioning the company to a commercial entity. The core strategy involves leveraging existing clinical data, intellectual property, and regulatory exclusivity to expedite the path to market for treatments addressing high unmet medical need in oncology.

Therapeutic Areas